Last reviewed · How we verify

NCT07082153: REVIVE-FIM

The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCI

Not yet recruiting NA Last updated 24 July 2025
What this trial tests

NA trial testing the coronary sinus balloon pump in STEMI in 10 participants. Not yet recruiting.

Timeline
12 August 2025
Primary endpoint
1 December 2025
3 March 2026

Quick facts

Lead sponsorShanghai MicroPort Rhythm MedTech Co., Ltd.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date12 August 2025
Primary completion1 December 2025
Estimated completion3 March 2026

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai MicroPort Rhythm MedTech Co., Ltd.

Who can join

Adults 18 to 80, any sex, with STEMI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter clinical investigation aiming to evaluate the safety and efficacy of the coronary sinus balloon pump in its first application in patients with acute ST-segment elevation myocardial infarction (STEMI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for STEMI

Currently open trials in the same condition.

Other Shanghai MicroPort Rhythm MedTech Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07082153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing